Syndrome News and Research

RSS

ACTION Ontario encourages provincial narcotics strategy announcement

ACTION Ontario, a non-profit group advocating on behalf of chronic pain sufferers, welcomes the announcement of a provincial narcotics strategy and encourages the government to act on the underlying issue of chronic pain.

30 Aug 2010

New research contradicts previous reports on blood-thinner clopidogrel

New findings by McMaster University researchers contradict earlier reports that people with a certain genetic make-up don't benefit from the blood-thinner clopidogrel, also known as Plavix.

30 Aug 2010

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

The international ATOLL study sponsored by the Assistance Publique - Hopitaux de Paris showed that enoxaparin reduced the composite of death, complication of myocardial infraction, procedure failure or major bleeding by 17% in comparison with standard heparin death, recurrent acute coronary syndrome or urgent revascularisation. The results of the ATOLL study were presented at the hotline session of the annual European Cardiology Congress (ESC 2010) in Stockholm, Sweden.

30 Aug 2010

New high throughput sequencing technology to identify genetic defects in rare diseases

The majority of rare diseases are hereditary. But despite significant progress in genome research, in most cases their exact cause remains unclear. The discovery of the underlying genetic defect is, however, a prerequisite for their definitive diagnosis and the development of innovative approaches to their treatment. Scientists at the Max Planck Institute for Molecular Genetics and the Institute of Medical Genetics at the Charit- Universit-tsmedizin - Berlin have succeeded in using a new process with which all of the genes in the human genome can be analysed simultaneously.

30 Aug 2010

Exmovere to release vital sign monitoring infant sleepwear

Exmovere Holdings, Inc., a biomedical engineering company, today announced plans to release vital sign monitoring infant sleepwear. Exmovere is in the advanced stages of taking to market a washable, conductive fabric-based biosensor pajama called "Exmobaby." Exmobaby is the first-ever baby garment developed for remote monitoring of heart rate, emotional state and behavior.

27 Aug 2010

Traumatic brain injury causes $6.8 billion worth of economic trauma in Texas

Each year in Texas, traumatic brain injury (TBI) causes an estimated $6.8 billion worth of economic trauma in terms of deaths, emergency room visits, hospitalizations and disability, according to a study commissioned by the CORE Health Foundation. To put that dollar amount in perspective, it equals Coca-Cola's corporate profit for fiscal 2009.

27 Aug 2010

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

The term "macrophage" conjures images of a hungry white blood cell gobbling invading bacteria. However, macrophages do much more than that. Not only do they act as antimicrobial warriors, they also play critical roles in immune regulation and wound-healing. They can respond to a variety of cellular signals and change their physiology in response to local cues.

27 Aug 2010

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

Cascade Technologies, Inc. announced today that its wholly owned subsidiary Spectral Molecular Imaging, Inc. (SMI) will complete development of its new product SkinSpect, aimed at early detection of melanoma by hyperspectral imaging, in mid-September 2010, significantly ahead of schedule.

27 Aug 2010

H1N1 flu increases complication in children with sickle cell anemia: Study

Children with sickle cell disease are especially hard-hit by the H1N1 flu strain, causing more life-threatening complications than the seasonal flu, according to a study from Johns Hopkins Children's Center.

27 Aug 2010

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Researchers have isolated a molecule, small enough to be used as a drug, that can shut down a dysfunctional immune response that causes deadly hemorrhagic shock, results in delayed death of heart attack patients, promotes rejection of transplanted organs and destroys joints in patients with rheumatoid arthritis, according to a paper published in Molecular Immunology.

27 Aug 2010

Battery of tests for quick assessment of cognitive abilities in Down syndrome patients

Neuroscientists in the Down Syndrome Research Group at the University of Arizona have created a battery of tests that quickly aid in the assessment of the cognitive abilities of persons with Down syndrome.

27 Aug 2010

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Amneal Pharmaceuticals, LLC is pleased to announce that it has received U.S. FDA approval to manufacture Spironolactone HCl tablets in 25 mg, 50 mg and 100 mg strengths effective July 2, 2010.

26 Aug 2010

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

Sermo, the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome.

26 Aug 2010

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Mental disorders, such as depression, anxiety disorders, addiction and schizophrenia are the core challenge of most health care systems around the world. In the EU alone, each year 27% of the total adult population - this corresponds to 83 Million citizens - suffer from mental disorders. Depression alone affects almost 20 million ranking in the EU as the most disabling disorder of all diseases.

26 Aug 2010

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

Atherotech Diagnostics Lab will exhibit its VAP Cholesterol Test in booth 105 at the National Lipid Association (NLA) Summer 2010 Clinical Lipid Update.

26 Aug 2010

Naringenin from grape fruits initiates increased fatty acid oxidation, inhibits vLDL production

Naringenin, an antioxidant derived from the bitter flavor of grapefruits and other citrus fruits, may cause the liver to break down fat while increasing insulin sensitivity, a process that naturally occurs during long periods of fasting.

26 Aug 2010

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

Afferent Pharmaceuticals, a clinical-stage biopharmaceutical company developing first-in-class, small molecule compounds that target P2X3 receptors, today announced preclinical in vivo results demonstrating that an investigational P2X3 receptor antagonist reduced experimentally induced bladder hyperactivity.

26 Aug 2010

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

ImmuneRegen BioSciences®, a wholly owned subsidiary of IR Biosciences Holdings Inc., today announced that the National Institute of Health/National Institute of Allergy and Infectious Disease, has awarded its research partner, the University of Rochester Medical Center (URMC), a $15 million five-year, continuation grant for studies that will utilize ImmuneRegen's Homspera.

25 Aug 2010

NexMed expands patent protection for Prostaglandin E1 -based products in Israel

NexMed, Inc., backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, today announced that the Israel Patent Office has issued an allowance notice for NexMed's patent application entitled, "Topical Compositions for Prostaglandin E1 Delivery."

24 Aug 2010

USPTO grants Taligen patent for TT30 lead product candidate

Taligen Therapeutics, a biotechnology company developing therapies that regulate the complement system to treat inflammatory and immune diseases, announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,759,304, entitled "Targeting Complement Factor H For Treatment of Diseases", covering the composition of matter for its lead product candidate, TT30, a novel fusion protein that selectively binds to complement activated cells to locally regulate the complement system.

24 Aug 2010

Syndrome News and Research

ACTION Ontario encourages provincial narcotics strategy announcement

New research contradicts previous reports on blood-thinner clopidogrel

ATOLL study favors enoxaparin over UFH for primary Percutaneous Coronary Intervention

New high throughput sequencing technology to identify genetic defects in rare diseases

Exmovere to release vital sign monitoring infant sleepwear

Traumatic brain injury causes $6.8 billion worth of economic trauma in Texas

David Mosser to discuss primary duty of macrophages at American Physiological Society conference

Spectral Molecular Imaging completes development of SkinSpect for melanoma detection

H1N1 flu increases complication in children with sickle cell anemia: Study

Researchers identify molecule to slow down dysfunctional immune response in hemorrhagic shock

Battery of tests for quick assessment of cognitive abilities in Down syndrome patients

Amneal Pharmaceuticals receives FDA approval for Spironolactone HCl tablets

Sermo report highlights physician opinions about investigational oral antiplatelet treatment for ACS

23rd European College of Neuropsychopharmacology Congress to be held 28 Aug - 1 Sep 2010 in Amsterdam

Atherotech Diagnostics to exhibit VAP Cholesterol Test at NLA Summer 2010 Clinical Update

Naringenin from grape fruits initiates increased fatty acid oxidation, inhibits vLDL production

Afferent Pharmaceuticals' P2X3 receptor antagonist reduces bladder hyperactivity

NIH awards University of Rochester Medical Center $15M grant for study with ImmuneRegen's Homspera

NexMed expands patent protection for Prostaglandin E1 -based products in Israel

USPTO grants Taligen patent for TT30 lead product candidate

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News